Tampa, United States
Catalent positions itself as a pivotal innovator in the healthcare sector, renowned for its expertise in advanced drug delivery technologies and manufacturing solutions. Although the specific founding date is undisclosed, its reputation as a global leader is augmented by its strategic acquisition of Paragon Bioservices.
This acquisition has substantially broadened Catalent's foothold in the gene therapy arena, particularly in viral vector development and manufacturing related to adeno-associated virus (AAV) vectors. With this move, Catalent solidifies its stature as a pioneer in biologics, protein development, and the creation of next-generation vaccines.
Despite the lack of specific details regarding industry categorization, headquarters location, and recent investment data, Catalent's strategic investments and market expansions suggest a robust potential for continued influence and growth within the pharmaceutical manufacturing landscape. Its commitment to innovation underscores its appeal to investors seeking transformative opportunities in health technology advancements.
